Income statement
SEK
Annual
| Metric | 2025 | 2025 | 2024 |
|---|---|---|---|
| Revenue | 4K | 174K | 266K |
| Gross Profit | -269K | -97K | -34K |
| Operating Income | -15M | -2M | -2M |
| EBITDA | -16M | -2M | -2M |
| Net Income | -15M | -974K | -2M |
| EPS (Diluted) | — | — | — |
Technology
Live Price
Offline$0.2458
+9.34% today
1Y Change
-92.90%
Window
Jun 25, 2025 → Jun 22, 2026
Coverage: 70 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CALLIDITAS THERAPEUTICS AB (CLTEF) is a Technology stock with a market cap of $11.24B and listed on OTC. The stock last traded around $0.25 and down 92.9% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of -97.6%, EPS growth of -891.3%, a dividend yield of 0.0%. What stands out right now is revenue -97.6%, EPS -891.3%, free cash flow 0.0% with operating margin -31.9% and ROIC -25.3%. Valuation already assumes a fairly strong business story at price/sales 9.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CLTEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Technology peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CLTEF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CLTEF Max Drawdown
-99.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CLTEF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$266.2K
+52.6% YoY
FY Net Income
-$1.9M
-90.8% YoY
Free Cash Flow
-$2.0M
-83.7% YoY
Revenue Growth
-97.6%
EPS Growth
-891.3%
Gross Margin
93.6%
Net Margin
-38.6%
Income statement
SEK
| Metric | 2025 | 2025 | 2024 |
|---|---|---|---|
| Revenue | 4K | 174K | 266K |
| Gross Profit | -269K | -97K | -34K |
| Operating Income | -15M | -2M | -2M |
| EBITDA | -16M | -2M | -2M |
| Net Income | -15M | -974K | -2M |
| EPS (Diluted) | — | — | — |
Balance sheet
SEK
| Metric | 2025 | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | 4M | 220K | 115K |
| Total Assets | 29M | 26M | 1M |
| Total Liabilities | 562K | 1M | 1M |
| Shareholder Equity | 28M | 25M | 147K |
| Total Debt | 0 | 418K | 0 |
| Net Debt | -4M | 198K | -115K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
-83.7% YoY
Capital Expenditures
21
+9.8% YoY
Free Cash Flow
2M
-83.7% YoY
Key ratios
Gross Margin
93.6%
Operating Margin
-31.9%
Net Margin
-38.6%
ROE
-84.7%
Debt / Equity
2.92x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.